XLON
OPTI
Market cap8mUSD
Oct 07, Last price
5.90GBP
1D
0.00%
1Q
-7.81%
Jan 2017
-90.33%
IPO
-99.81%
Name
OptiBiotix Health PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, and tailored blends intended for integration into food products, nutritional supplements, and active ingredients. Their groundbreaking work aims to positively influence human physiology and yield substantial health benefits. Among its diverse product portfolio are Slimbiome, a natural ingredient for healthy and satiety-driven weight management, and SlimBiome Medical, a supplemental aid for weight control. Other offerings include CholBiome, a dietary supplement for maintaining healthy cholesterol; Lactobacillus plantarum LPLDL, a probiotic supporting cardiovascular health and overall well-being; LPGOS, a galactooligosaccharide utilized in food applications to mitigate cardiovascular risk factors and enhance general health; WellBiome, a functional fiber and mineral blend designed to bolster gut microbiome diversity and promote wellness; and Sweetbiotix, a sweetener for use in various foods and beverages. Ultimately, OptiBiotix's innovations are designed to prevent and manage prevalent chronic lifestyle diseases, including obesity, high cholesterol, and diabetes. The company was founded in 2012.
Key people
Non-Executive Chairman of the Board · since 2018
Stephen O'Hara
Chief Executive Officer, Executive Director · since 2015
Frederic Narbel
Executive Sales and Marketing Director · since 2019
Luis Gosalbez
Director of Business Development · since 2016
Sofia Kolyda
Director of Research and Development · since 2018
Co-Chairman of the Board · since 2015
Gareth Allan Barker
Non-Executive Director · since 2014
Non-Executive Director · since 2018
Jan Peter Fredrik Wennstrom
Non-Executive Director · since 2016
Headquarters & legal address
Innovation Centre Innovation Way
Heslington
York YO10 5DG
GB
Heslington
York YO10 5DG
GB
Previous name
DUCAT VENTURES PLC
Previous name
CERES MEDIA INTERNATIONAL PLC
Previous name
HARTFIELD SECURITIES PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑11 | 2017‑11 | 2016‑11 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||